{
    "2019-05-21": [
        [
            {
                "time": "2018-03-15",
                "original_text": "Why This Biotech Stock Succeeded In Colon Cancer As Others Struggled",
                "features": {
                    "keywords": [
                        "Biotech",
                        "Colon Cancer",
                        "Succeeded",
                        "Struggled"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-10",
                "original_text": "Here's Why Array BioPharma Is Surging Today",
                "features": {
                    "keywords": [
                        "Array BioPharma",
                        "Surging",
                        "Today"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-05-20",
                "original_text": "Lilly's Mirikizumab Met Primary Endpoint and Key Secondary Endpoints in Phase 2 Study, Including Reductions of Gastrointestinal Lesions",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Mirikizumab",
                        "Phase 2",
                        "Gastrointestinal Lesions",
                        "Reductions"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-06-25",
                "original_text": "Merck agrees $1bn deal to buy biopharmaceutical company Peloton",
                "features": {
                    "keywords": [
                        "Merck",
                        "$1bn",
                        "deal",
                        "Peloton",
                        "biopharmaceutical"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}